Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Extranodal NK T Cell LymphomaNK-Cell Leukemia
Interventions
BIOLOGICAL

Anti-CD56 CAR T

CAR T cells were pretreated at -5 days before retransfusion (FC regimen: fludarabine: 30mg/m2×3 days, cyclophosphamide: 750mg/m2×1 day). Anti CD56-CAR T cells were transfused back to the patient 2 days after the end of chemotherapy. 30 to 60 minutes before CAR T cell infusion, patients were given 325 to 650 mg of acetaminophen orally to prevent infusion-related reactions; If fever occurred on the day of CAR T cell infusion, lasted less than 24 hours, and had no other toxicity, it was attributed to the infusion T cell response.

Trial Locations (1)

221002

RECRUITING

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

All Listed Sponsors
lead

The Affiliated Hospital of Xuzhou Medical University

OTHER